Literature DB >> 28979700

Oridonin ameliorates lipopolysaccharide/D-galactosamine-induced acute liver injury in mice via inhibition of apoptosis.

Yilin Deng1, Chen Chen2, Heguo Yu3, Hua Diao3, Cuicui Shi1, Yugang Wang2, Guangming Li1, Min Shi2.   

Abstract

We investigated the protective effects exerted by oridonin, the main active constituent of the Chinese medicinal herb Rabdosiarubescens, against lipopolysaccharide (LPS)/D-galactosamine (D-Gal)-induced acute liver injury (ALI). An ALI model was induced in mice using LPS (40 μg/0.5 ml) and D-Gal (5 mg/0.5 ml). The mice were randomly divided into the following five groups of six mice each: one control group (a), one ALI group (b), two oridonin treatment groups (c and d), and one oridonin control group (e). Oridonin (0.2 mg/0.5 ml) was administered once 1 h prior to the LPS/D-Gal challenge in group c and a total of three times over a period of four days, with the last dose given at 1 h before the LPS/D-Gal challenge, in group d. Pretreatment with oridonin improved the survival rate, alleviated histopathological abnormalities, and suppressed plasma aminotransferases in the LPS/D-Gal-challenged mice. Importantly, oridonin attenuated LPS/D-Gal-induced apoptosis in hepatocytes by reducing pro-apoptotic signals (P<0.05), such as tumor necrosis factor-α (TNF-α) and c-Jun N-terminal kinases (JNK). Furthermore, JNK-associated mitochondrial pro-apoptotic proteins were also suppressed by pretreatment with oridonin. Taken together, these data show that oridonin exerts protective effects against LPS/D-Gal-induced ALI in mice via a mechanism that may involve the suppression of the pro-apoptotic cytokine TNF-α and JNK-associated pro-apoptotic signaling.

Entities:  

Keywords:  D-galactosamine (D-Gal); Lipopolysaccharide (LPS); apoptosis; drug-induced liver injury; oridonin

Year:  2017        PMID: 28979700      PMCID: PMC5622269     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  23 in total

Review 1.  Mechanisms of hepatotoxicity.

Authors:  Hartmut Jaeschke; Gregory J Gores; Arthur I Cederbaum; Jack A Hinson; Dominique Pessayre; John J Lemasters
Journal:  Toxicol Sci       Date:  2002-02       Impact factor: 4.849

2.  Oridonin suppresses transplant rejection by depleting T cells from the periphery.

Authors:  Wenzhi Guo; Peiguo Zheng; Jiakai Zhang; Liang Ming; Chuang Zhou; Shuijun Zhang
Journal:  Int Immunopharmacol       Date:  2013-11-06       Impact factor: 4.932

Review 3.  Caspase functions in cell death and disease.

Authors:  David R McIlwain; Thorsten Berger; Tak W Mak
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-04-01       Impact factor: 10.005

4.  LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor.

Authors:  M Nowak; G C Gaines; J Rosenberg; R Minter; F R Bahjat; J Rectenwald; S L MacKay; C K Edwards; L L Moldawer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-05       Impact factor: 3.619

5.  Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand.

Authors:  M D Josephs; F R Bahjat; K Fukuzuka; R Ksontini; C C Solorzano; C K Edwards; C L Tannahill; S L MacKay; E M Copeland; L L Moldawer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-05       Impact factor: 3.619

Review 6.  Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics.

Authors:  Chun-yang Li; En-qin Wang; Yan Cheng; Jin-ku Bao
Journal:  Int J Biochem Cell Biol       Date:  2011-02-02       Impact factor: 5.085

7.  CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses.

Authors:  Dass S Vinay; Beom K Choi; Jun S Bae; Won Y Kim; Bryan M Gebhardt; Byoung S Kwon
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

Review 8.  D-galactosamine lethality model: scope and limitations.

Authors:  Richard Silverstein
Journal:  J Endotoxin Res       Date:  2004

9.  Differential requirement for c-Jun NH2-terminal kinase in TNFalpha- and Fas-mediated apoptosis in hepatocytes.

Authors:  Robert F Schwabe; Hiroshi Uchinami; Ting Qian; Brydon L Bennett; John J Lemasters; David A Brenner
Journal:  FASEB J       Date:  2004-02-06       Impact factor: 5.191

Review 10.  Mechanisms of immune-mediated liver injury.

Authors:  David H Adams; Cynthia Ju; Shashi K Ramaiah; Jack Uetrecht; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2010-01-13       Impact factor: 4.849

View more
  6 in total

1.  Hepatoprotective effect of diallyl trisulfide against lipopolysaccharide and D-galactosamine induced acute liver failure in mice via suppressing inflammation and apoptosis.

Authors:  Ziqiang Yu; Yun Ding; Tao Zeng; Xiulan Zhao; Cuili Zhang
Journal:  Toxicol Res (Camb)       Date:  2022-02-19       Impact factor: 2.680

2.  Protective Effects of Oridonin on Acute Liver Injury via Impeding Posttranslational Modifications of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in the Toll-Like Receptor 4 (TLR4) Signaling Pathway.

Authors:  Min Shi; Yilin Deng; Heguo Yu; Ling Xu; Cuicui Shi; Jiong Chen; Guangming Li; Yiqi Du; Yu-Gang Wang
Journal:  Mediators Inflamm       Date:  2019-09-12       Impact factor: 4.711

3.  Oridonin Attenuates Cisplatin-Induced Acute Kidney Injury via Inhibiting Oxidative Stress, Apoptosis, and Inflammation in Mice.

Authors:  Hyemin Gu; Mi-Gyeong Gwon; Jong Hyun Kim; Jaechan Leem; Sun-Jae Lee
Journal:  Biomed Res Int       Date:  2022-04-16       Impact factor: 3.246

Review 4.  Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance.

Authors:  Xi Liu; Jimin Xu; Jia Zhou; Qiang Shen
Journal:  Genes Dis       Date:  2020-07-05

5.  Oridonin ameliorates carbon tetrachloride-induced liver fibrosis in mice through inhibition of the NLRP3 inflammasome.

Authors:  Dong Liu; Hailong Qin; Bixian Yang; Bin Du; Xuelin Yun
Journal:  Drug Dev Res       Date:  2020-03-26       Impact factor: 4.360

Review 6.  Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity.

Authors:  Xiang Li; Chuan-Tao Zhang; Wei Ma; Xin Xie; Qun Huang
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.